Bifidobacterium bifidum G9-1 Intake Improves Gastrointestinal Symptoms in Type 2 Diabetes Mellitus: An Open-Label, Randomized Controlled Trial (Binary STAR Study).
- 2026-04-22
- RCT · n = 100
- Diabetes, obesity & metabolism 28(7)
- Genki Kobayashi
- Yoshitaka Hashimoto
- Tomoyuki Matsuyama
- Noriyuki Kitagawa
- Saori Majima
- Takafumi Senmaru
- Emi Ushigome
- Hiroshi Okada
- Naoko Nakanishi
- Masahide Hamaguchi
- Michiaki Fukui
- PubMed: 42017290
- DOI: 10.1111/dom.70805
- High evidence
- Large Human Trial
- Clinical
Assessment of faecal short-chain fatty acids (SCFAs) revealed no significant changes associated with BBG9-1 administration.
- Effect
- Neutral
- Effect size
- Small
- Significant
- No
- Dose
- 12 mg/day